Skip to main content

Validation of a novel antiviral drug candidate against influenza

Project description

Novel drugs stop influenza replication

Influenza viruses are responsible for the seasonal flu, affecting millions of people worldwide every year. Given the potential of influenza to cause pandemics with devastating effects on human lives and the economy, there is a pressing need for effective antiviral drugs with a reduced risk of causing viral escape. Scientists of the EU-funded FluAttack project have identified a new family of molecules as potent inhibitors of influenza viruses. These molecules target a cellular function paramount to virus survival and will undergo further testing and characterisation in models of influenza infection. The project aims to support the future development and pre-clinical validation of these anti-flu drugs.

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 139 081

Beneficiaries (2)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 139 081
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
CNRS INNOVATION
France
EU contribution
€ 10 919
Address
Boulevard Exelmans 83
75016 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)